Hemispherx secures $75 million through at-the-market stock offering

Maxim assists in funding commercialization of Alferon and Ampligen

By Devika Patel

Knoxville, Tenn., Oct. 5 - Hemispherx Biopharma, Inc. negotiated a $75 million at-the-market offering of its common stock, according to a prospectus supplement filed Friday with the Securities and Exchange Commission.

Maxim Group LLC is the agent.

Proceeds will be used for the commercialization of Alferon and Ampligen, along with general corporate purposes, which may include working capital, capital expenditures, research and development, regulatory affairs, clinical trials, acquisitions and investments and the repayment, refinancing, redemption or repurchase of debt or capital stock.

The company's stock (NYSE: HEB) closed at a price of $0.78 per share on Oct. 1.

Philadelphia-based Hemispherx develops drugs to treat debilitating disorders, like viral diseases and immune-system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.